Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AML

Ziftomenib demonstrated significant clinical benefit and deep responses in patients with heavily pretreated, relapsed/refractory <i>NPM1</i>-m AML. Ziftomenib was well tolerated with a safety profile consistent with previous studies, including manageable differentiation syndrome, lack of clinically significant QTc prolongation, and low rates of myelosuppression.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-09-25
DOI
https://doi.org/10.1200/jco-25-01694
Citations
11
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
19.47
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML

Mahmoud Elsawy, Arnaud Pigneux, Pau Montesinos, James McCloskey et al.
11 citations
Journal of Clinical Oncology
Acute Myeloid Leukemia Research
19.47
article

Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML

Mahmoud Elsawy, Arnaud Pigneux, Pau Montesinos, James McCloskey, Lionel Adès, Marcie Riches, Mohamad Khawandanah, Adolfo de la Fuente, Gail J. Roboz, Caterina Giannini, Mithun Vinod Shah, Pierre Péterlin, Francesco Lanza, Jessica K. Altman, Adrian Schwarzer, Amitava Mitra, James M. Foran, Daniel Corum, Robert L. Redner, Harris S. Soifer, Cristina Papayannidis, Maria R. Baer, Harry Paul Erba, Dries Deeren, Frédéric Barabé, Marilyn Tabachri, Kristen Marie Pettit, Eduardo Rodríguez‐Arbolí, Teresa Bernal, Amir T. Fathi, Suresh Kumar Balasubramanian, Yazan F. Madanat, Jordi Esteve Reyner, Agustín Penedo, Zijing Zhang, Florian Heinrich Heidel, Mollie Leoni, Adriano Venditti
article en
11 citations

Abstract

Ziftomenib demonstrated significant clinical benefit and deep responses in patients with heavily pretreated, relapsed/refractory <i>NPM1</i>-m AML. Ziftomenib was well tolerated with a safety profile consistent with previous studies, including manageable differentiation syndrome, lack of clinically significant QTc prolongation, and low rates of myelosuppression.

Journal of Clinical OncologyVol. 43(31)
Northwestern University (US), Universitat Autònoma de Barcelona (ES), University of Maryland, Baltimore (US), Roswell Park Comprehensive Cancer Center (US), Hackensack University Medical Center (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Wayne State University (US), Vanderbilt University (US), Cornell University (US), University of Michigan (US), Hotel Dieu Hospital (CA), Hôpital Maisonneuve-Rosemont (CA), Centre Hospitalier Universitaire de Lille (FR), Hospital Universitari i Politècnic La Fe (ES), Medizinische Hochschule Hannover (DE), Massachusetts General Hospital (US), Fred Hutch Cancer Center (US), The Barbara Ann Karmanos Cancer Institute (US), Hôpital Lyon Sud (FR), Istituto di Ematologia di Bologna (IT), Hôpital Cardiologique du Haut-Lévêque (FR), Mayo Clinic in Arizona (US), Duke Medical Center (US), Centre d'Investigation Clinique de Nantes (FR), UPMC Hillman Cancer Center (US), Instituto de Biomedicina de Sevilla (ES), University of Pittsburgh Medical Center (US), Hôpital Saint-Louis (FR), Mayo Clinic in Florida (US), Hospital Universitario Virgen del Rocío (ES), Kura Oncology (United States) (US), MD Anderson Cancer Center Madrid (ES), Banner MD Anderson Cancer Center, U-M Rogel Cancer Center (US), Vanderbilt-Ingram Cancer Center, Duke Cancer Institute, University of Oklahoma Health Sciences Center (US), Universidad de Sevilla (ES), The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 1%
Acute Myeloid Leukemia Research
19.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.